News | June 17, 2008

MEDRAD Receives Green Light from FDA for FDG Infusion System

June 18, 2008 – MEDRAD gained FDA 510(k) clearance for a new Fluorodeoxyglucose (FDG) infusion system for positron emission tomography/computed tomography (PET/CT) imaging procedures, reportedly the first infusion system available in the U.S. to automate the FDG delivery process.

The new PET infusion system, Intego, reportedly enables the healthcare provider to easily administer FDG at any time throughout the day and enhances the clinician's ability to deliver FDG with precision, flexibility and safety.

The system automatically extracts a patient dose from a multidose vial and delivers it directly to the patient, virtually eliminating manual dose preparation and handling, and the corresponding radiation exposure to the technologist.

With the Intego System's dose-on-demand capability, the prescribed dose can be delivered when the patient and technologist are ready, letting technologists respond to schedule changes, patient delays, and add-on patients. The system has new features including real-time dose availability information, an integrated ionization chamber and an optional weight-based dose calculation, allowing the healthcare provider to more precisely customize each patient's dose.

Safety features include a tungsten multidose vial shield, a fully lead-lined mobile cart and an automated saline flush to remove residual FDG from the line after each infusion.

The company is working with FDG suppliers to provide FDG in multidose vials and vial shields compatible with the Intego System and recently announced a distribution and co-marketing agreement with the largest PET radiopharmacy network, PETNET Solutions, a fully owned subsidiary of Siemens Medical Solutions.

For more information: www.medrad.com

Related Content

Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
Videos | Magnetic Resonance Imaging (MRI) | December 19, 2017
Emanuel Kanal, M.D., director of MRI services and professor of radiology and neuroradiology at the University of Pitt
The FDA issued new warnings on MRI gadolinium contrast agents. (GBCAs)

The FDA issued new warnings on MRI gadolinium contrast agents. 

Feature | Magnetic Resonance Imaging (MRI) | December 19, 2017
The U.S.
Brainlab Contrast Clearance Analysis Software Receives FDA 510(k) Clearance
Technology | Contrast Media | December 12, 2017
Brainlab announced U.S. Food and Drug Administration (FDA) clearance of its Contrast Clearance Analysis methodology,...
Sectra Offers Gadolinium Tracking Functionality in DoseTrack Software
Technology | Contrast Media | December 11, 2017
December 11, 2017 — Sectra recently announced the global introduction of gadolinium tracking in its dose monitoring s
Videos | Magnetic Resonance Imaging (MRI) | December 07, 2017
Max Wintermark, M.D., professor of radiology and chief of neuroradiology, Stanford Hospital and Clinics, discussed MR
Guerbet to Participate in French Interventional Radiology Conference
News | Contrast Media | October 10, 2017
Guerbet announced it will be taking part in the 65th edition of the Journées Francophones de Radiologie (JFR) that will...
Trends in contrast media used in magnetic resonance imaging and computed tomography

Image courtesy of Bayer

Feature | Contrast Media | October 04, 2017 | By Dave Fornell
Over the past decade, several clinical studies have shown gadolinium-based magnetic resonance imaging (MRI) contrast...
FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents
News | Contrast Media | September 12, 2017
The U.S. Food and Drug Administration’s (FDA) Medical Imaging Drugs Advisory Committee (MIDAC) voted overwhelmingly...
Overlay Init